# Requires insurers to cover the substitution of a brand name prescription drug when the federal food and drug administration has declared that there is a supply issue with a generic drug

**Bill ID:** A10185
**Session:** 2024
**Sponsor:** Phara Souffrant Forrest
**Status:** In Assembly Committee
**PDF:** [A10185 PDF](https://legislation.nysenate.gov/pdf/bills/2024/A10185)

## Summary

Requires insurers to cover the substitution of a brand name prescription drug when the federal food and drug administration has declared that there is a supply issue with a generic drug.

---

## Full Text

S T A T E  O F  N E W  Y O R K
 ________________________________________________________________________
 
  10185
 
  I N  A S S E M B L Y
 
  May 10, 2024
  ___________
 
 Introduced  by COMMITTEE ON RULES -- (at request of M. of A. Forrest) --
  read once and referred to the Committee on Insurance
 
 AN ACT to amend the insurance law, in  relation  to  substituting  brand
  name prescription drugs in the case of a drug shortage
 
  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:

  Section 1. Section 3242 of the insurance law is amended  by  adding  a
 new subsection (d) to read as follows:
  (D) (1) AS USED IN THIS SUBSECTION:
  (A)  "ELIGIBLE  PRESCRIPTION  DRUG" MEANS A PRESCRIPTION DRUG APPROVED
 UNDER 21 U.S.C. 355(C) THAT IS NOT UNDER PATENT.
  (B) "GENERIC DRUG" MEANS A DRUG THAT IS APPROVED PURSUANT TO AN APPLI-
 CATION REFERENCING AN ELIGIBLE PRESCRIPTION DRUG THAT IS SUBMITTED UNDER
 SUBSECTION (J) OF SECTION 505 OF THE FEDERAL FOOD,  DRUG,  AND  COSMETIC
 ACT, 21 U.S.C. 355.
  (C)  "SUPPLY  ISSUE" MEANS A DRUG SHORTAGE OR MEANINGFUL DISRUPTION AS
 DEFINED IN 21 U.S.C. 356(C).
  (2) IN THE EVENT AN AB-RATED  GENERIC  EQUIVALENT  OR  INTERCHANGEABLE
 BIOLOGICAL  PRODUCT  FOR  AN ELIGIBLE PRESCRIPTION DRUG IS COVERED IN AN
 INSURER'S FORMULARY AND SUCH GENERIC DRUG EQUIVALENT IS UNAVAILABLE  DUE
 TO A SUPPLY ISSUE WHICH HAS BEEN RECOGNIZED BY THE FEDERAL FOOD AND DRUG
 ADMINISTRATION  PURSUANT  TO  21  U.S.C.  356E  AND THE DOSAGE CANNOT BE
 ADJUSTED, AN INSURER THAT DELIVERS OR ISSUES FOR DELIVERY IN THIS  STATE
 A  POLICY  THAT  PROVIDES  COVERAGE FOR PRESCRIPTION DRUGS SHALL PROVIDE
 COVERAGE FOR A BRAND NAME ELIGIBLE PRESCRIPTION DRUG TO AN  INSURED  WHO
 IS  ALREADY  RECEIVING SUCH PRESCRIPTION DRUG AS A GENERIC EQUIVALENT OR
 HAS BEEN DIAGNOSED WITH OR PRESENTED WITH A CONDITION ON OR PRIOR TO THE
 START OF THE PLAN YEAR THAT IS TREATED  BY  SUCH  ELIGIBLE  PRESCRIPTION
 DRUG OR IS AN ELIGIBLE PRESCRIPTION DRUG THAT IS OR WOULD BE PART OF THE
 INSURED'S TREATMENT REGIMEN FOR SUCH CONDITION. SUCH BRAND NAME ELIGIBLE
 PRESCRIPTION  DRUG SHALL BE COVERED AT THE SAME LEVEL OF COVERAGE AS THE
 GENERIC DRUG IN THE INSURER'S FORMULARY UNTIL SUCH TIME  AS  THE  SUPPLY
 ISSUE  IS  RESOLVED  AND THE DRUG HAS BEEN REMOVED FROM THE FEDERAL FOOD
 AND DRUG ADMINISTRATION'S SHORTAGE LIST.
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
  [ ] is old law to be omitted.
  LBD15336-01-4
 A. 10185  2
 
  ยง 2. Section 4329 of the insurance law is  amended  by  adding  a  new
 subsection (d) to read as follows:
  (D) (1) AS USED IN THIS SUBSECTION:
  (A)  "ELIGIBLE  PRESCRIPTION  DRUG" MEANS A PRESCRIPTION DRUG APPROVED
 UNDER 21 U.S.C. 355(C) THAT IS NOT UNDER PATENT.
  (B) "GENERIC DRUG" MEANS A DRUG THAT IS APPROVED PURSUANT TO AN APPLI-
 CATION REFERENCING AN ELIGIBLE PRESCRIPTION DRUG THAT IS SUBMITTED UNDER
 SUBSECTION (J) OF SECTION 505 OF THE FEDERAL FOOD,  DRUG,  AND  COSMETIC
 ACT, 21 U.S.C. 355.
  (C)  "SUPPLY  ISSUE" MEANS A DRUG SHORTAGE OR MEANINGFUL DISRUPTION AS
 DEFINED IN 21 U.S.C. 356(C).
  (2) IN THE EVENT AN AB-RATED  GENERIC  EQUIVALENT  OR  INTERCHANGEABLE
 BIOLOGICAL  PRODUCT  FOR  AN ELIGIBLE PRESCRIPTION DRUG IS COVERED IN AN
 INSURER'S FORMULARY AND SUCH GENERIC DRUG EQUIVALENT IS UNAVAILABLE  DUE
 TO A SUPPLY ISSUE WHICH HAS BEEN RECOGNIZED BY THE FEDERAL FOOD AND DRUG
 ADMINISTRATION  PURSUANT  TO  21  U.S.C.  356E  AND THE DOSAGE CANNOT BE
 ADJUSTED, A CORPORATION SUBJECT TO THE PROVISIONS OF THIS  ARTICLE  THAT
 ISSUES  A  CONTRACT  THAT PROVIDES COVERAGE FOR PRESCRIPTION DRUGS SHALL
 PROVIDE COVERAGE FOR A BRAND  NAME  ELIGIBLE  PRESCRIPTION  DRUG  TO  AN
 INSURED  WHO  IS  ALREADY  RECEIVING SUCH PRESCRIPTION DRUG AS A GENERIC
 EQUIVALENT OR HAS BEEN DIAGNOSED WITH OR PRESENTED WITH A  CONDITION  ON
 OR  PRIOR TO THE START OF THE PLAN YEAR THAT IS TREATED BY SUCH ELIGIBLE
 PRESCRIPTION DRUG OR IS AN ELIGIBLE PRESCRIPTION DRUG THAT IS  OR  WOULD
 BE  PART  OF  THE  INSURED'S  TREATMENT REGIMEN FOR SUCH CONDITION. SUCH
 BRAND NAME ELIGIBLE PRESCRIPTION DRUG SHALL BE COVERED AT THE SAME LEVEL
 OF COVERAGE AS THE GENERIC DRUG IN THE INSURER'S  FORMULARY  UNTIL  SUCH
 TIME  AS THE SUPPLY ISSUE IS RESOLVED AND THE DRUG HAS BEEN REMOVED FROM
 THE FEDERAL FOOD AND DRUG ADMINISTRATION'S SHORTAGE LIST.
  ยง 3. This act shall take effect immediately.